Bolt Biotherapeutics, Inc. business relationships
Companies named in Bolt Biotherapeutics, Inc.’s 10-K filed 2026-03-12, and public companies whose annual reports name Bolt Biotherapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.0 / 10
- AI naming
- <1 / 100 Top 71% in its category
- Agent readiness
- 20 / 100
- AI adoption
- 0 / 100
Named in Bolt Biotherapeutics, Inc.’s annual report 4
“In May 2021, we entered into a License and Collaboration Agreement with Genmab A/S to evaluate Genmab antibodies in combination with our immune-stimulating linker-payload technology for the discovery and development of next-generation ISACs.” SEC filing
“Joint Development and License Agreement with Toray Industries, Inc. ("Toray")” SEC filing
“These include our collaborations with Toray Industries, Inc., or Toray, Genmab A/S, or Genmab, and Innovent Biologics, Inc., or Innovent.” SEC filing
- Innovent Biologics (IVBXF)Partner-
“In August 2021, we entered into a License and Collaboration Agreement with Innovent Biologics to leverage Innovent's proprietary therapeutic antibody portfolio and antibody discovery capability against undisclosed oncology targets in combination with our Boltbody ISAC technology and myeloid biology...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.